Tech Company Financing Transactions
Keros Therapeutics Funding Round
Arkin Bio-Ventures, Global Health Sciences Fund and Medison Pharma joined a $23 million Series B funding round for Keros Therapeutics. The funding round was announced on 1/9/2019.
Transaction Overview
Company Name
Announced On
1/9/2019
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from this financing will be used to advance Keros' two lead programs from preclinical validation through clinical proof-of-concept.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
99 Hayden Ave. Building E 120
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Not Recorded
Overview
Keros Therapeutics (Nasdaq: KROS) harnesses the knowledge of leading physician researchers and medical experts in the discovery and development of novel proprietary therapeutics for neuromuscular diseases. Headquartered in Lexington, Massachusetts, Keros Therapeutics is led by President and CEO Dr. Jasbir Seehra, who has over three decades of hands-on experience creating first-tier drug therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jasbir Seehra
Chief Financial Officer
Keith Regnante
Chief Medical Officer
Claudia Ordonez
Vice President
Jenn Lachey
Browse more venture capital transactions:
Prev: 1/9/2019: Carson Living venture capital transaction
Next: 1/9/2019: Flytrex venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs